A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity

Trial Profile

A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Delirium; Pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 Jun 2015.
    • 11 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2014 to 1 Jun 2015.
    • 12 Dec 2013 Planned number of patients changed from 35 to 20 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top